Education
About Us
Working with TipRanks
Follow Us
Edwards Lifesciences (EW)
NYSE:EW
EW Stock Chart & Stats
$86.82
$0.80(1.09%)
At close: 4:00 PM EST
$86.82
$0.80(1.09%)
Day’s Range― - ―
52-Week Range$65.94 - $87.21
Previous CloseN/A
Volume821.68K
Average Volume (3M)4.94M
Market Cap
$50.38B
Enterprise Value$42.41B
Total Cash (Recent Filing)$3.84B
Total Debt (Recent Filing)$700.30M
Price to Earnings (P/E)37.0
Beta0.72
Next Earnings
Feb 04, 2026EPS Estimate
0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.67
Shares Outstanding580,300,000
10 Day Avg. Volume4,118,622
30 Day Avg. Volume4,937,264
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)4.43
Price to Sales (P/S)8.13
P/FCF Ratio152.63
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue7.21
Enterprise Value/Gross Profit9.21
Enterprise Value/Ebitda24.34
Forecast
1Y Price Target
$93.57Price Target Upside7.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering24
EPS Forecast (FY)2.59
Revenue Forecast (FY)$6.04B
Bulls Say, Bears Say
Bulls Say
EarningsThe company's Q3 revenue and EPS soundly beat Street forecasts, showcasing strong financial performance.
Market OpportunitiesPascal and Evoque continue to drive momentum in the large market opportunities of mitral and tricuspid disease.
Product PerformanceTAVR sales grew 11% on a constant currency basis, indicating strong demand and market presence.
Bears Say
Clinical Trial PerformanceThe performance of TAVR in the P3 trial continues to get worse, and the long-term outcomes should still be monitored and questioned.
Coverage ConcernsTiming for CMS coverage is still uncertain, especially with government shutdown.
Growth UncertaintyUncertainty remains about whether the sustainable mid-term TAVR growth trajectory is better than mid-to-high single digits.
Edwards Lifesciences News
EW FAQ
What was Edwards Lifesciences’s price range in the past 12 months?
Edwards Lifesciences lowest stock price was $65.94 and its highest was $87.20 in the past 12 months.
What is Edwards Lifesciences’s market cap?
Edwards Lifesciences’s market cap is $50.38B.
When is Edwards Lifesciences’s upcoming earnings report date?
Edwards Lifesciences’s upcoming earnings report date is Feb 04, 2026 which is in 69 days.
How were Edwards Lifesciences’s earnings last quarter?
Edwards Lifesciences released its earnings results on Oct 30, 2025. The company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.596 by $0.074.
Is Edwards Lifesciences overvalued?
According to Wall Street analysts Edwards Lifesciences’s price is currently Undervalued.
Does Edwards Lifesciences pay dividends?
Edwards Lifesciences does not currently pay dividends.
What is Edwards Lifesciences’s EPS estimate?
Edwards Lifesciences’s EPS estimate is 0.62.
How many shares outstanding does Edwards Lifesciences have?
Edwards Lifesciences has 580,300,000 shares outstanding.
What happened to Edwards Lifesciences’s price movement after its last earnings report?
Edwards Lifesciences reported an EPS of $0.67 in its last earnings report, beating expectations of $0.596. Following the earnings report the stock price went down -1.234%.
Which hedge fund is a major shareholder of Edwards Lifesciences?
Currently, no hedge funds are holding shares in EW
Edwards Lifesciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$93.57 (7.77% Upside)
$93.57 (7.77% Upside)
Blogger Sentiment
Bullish
EW Sentiment 80%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 2.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 10.8%
Last 30 Days ▲ 19.0%
Last 30 Days ▲ 19.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.19%
12-Months-Change
Fundamentals
Return on Equity
13.59%
Trailing 12-Months
Asset Growth
2.32%
Trailing 12-Months
Company Description
Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
EW Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Edwards Lifesciences reported strong quarterly performance with significant sales growth across multiple segments, increased full-year guidance, and positive clinical data presentations. However, there were some concerns about declining gross profit margins and upcoming changes in financial leadership.View all EW earnings summariesEW Net sales Breakdown
75.49% Transcatheter Aortic Valve Replacement
18.04% Surgical Structural Heart
6.47% Transcatheter Mitral and Tricuspid Therapies
EW Stock 12 Month Forecast
Average Price Target
$93.57
▲(7.77% Upside)
Technical Analysis
Ownership Overview
0.21% Insiders
24.24% Mutual Funds
16.65% Other Institutional Investors
34.51% Public Companies and
Individual Investors